Abstract
AbstractThe purpose of this chapter is threefold.Firstly, it is an honor to be included in this Festschrift, a recognition and celebration of the enormous contribution Professor Richard Baum has made to the field of nuclear medicine. I would like to write a few words as to why Richard’s contribution to nuclear medicine and theranostics has been so important from a commercial perspective, and why we need more innovators like him. Secondly, I want to review some of the reasons why, despite enormous potential, the field of nuclear medicine has not been as commercially successful as it could be, and the pitfalls we must address in order to deliver in the future. Finally, I’d like to highlight some of the areas that I am most excited about from a commercial perspective that will likely define the field over the next decade.I’ve spent 20 years hunting money for imaging and nuclear medicine companies and over that time, through varying degrees of economic prosperity, I have received a great deal of candid feedback about how investors view the nuclear medicine industry. These perceptions offer provocative insights into our industry and I believe they are worth sharing, both for information and entertainment. Not all opinions will garner agreement.
Publisher
Springer International Publishing
Reference55 articles.
1. ImaginAb, Inc. http://www.imaginab.com. Accessed 19 Jun 2020.
2. Wu AM, Senter BD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23(9):1137–46. https://doi.org/10.1038/nbt1141.
3. Kulkarni HR, Singh A, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the bad Berka experience since 2013. J Nucl Med. 2016;57(3):97S–104S. https://doi.org/10.2967/jnumed.115.170167.
4. Perriello B. Report: Lantheus spikes IPO plans. Mass device. 2014. https://www.massdevice.com/report-lantheus-spikes-ipo-plans/. Accessed 19 Jun 2020.
5. Timmerman L. Why good drugs sometimes fail: the Bexxar Story. Xconomy. 2013. https://xconomy.com/national/2013/08/26/why-good-drugs-sometimes-fail-in-the-market-the-bexxar-story/. Accessed 19 Jun 2020.